Protalix BioTherapeutics (NYSE:PLX) Price Target Raised to $15.00

Posted by Renee Jackson on Feb 6th, 2025

Protalix BioTherapeutics (NYSE:PLX – Free Report) had its price target hoisted by HC Wainwright from $10.00 to $15.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2024 earnings at $0.06 EPS, FY2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS and FY2025 earnings at $0.19 EPS.

Separately, StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 24th.

Read Our Latest Report on Protalix BioTherapeutics

Protalix BioTherapeutics Trading Up 6.0 %

PLX stock opened at $2.67 on Monday. The stock has a market capitalization of $196.59 million, a price-to-earnings ratio of -20.54 and a beta of 0.75. The firm’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $1.43. Protalix BioTherapeutics has a 12-month low of $0.82 and a 12-month high of $2.71.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd purchased a new position in shares of Protalix BioTherapeutics in the 4th quarter worth about $35,000. PFG Investments LLC bought a new stake in Protalix BioTherapeutics during the 4th quarter valued at about $39,000. Sanctuary Advisors LLC bought a new stake in Protalix BioTherapeutics during the 3rd quarter valued at about $38,000. Virtu Financial LLC purchased a new position in Protalix BioTherapeutics in the third quarter worth about $44,000. Finally, XTX Topco Ltd bought a new position in shares of Protalix BioTherapeutics in the third quarter worth approximately $36,000. 16.53% of the stock is owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

(Get Free Report)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.